Get a Quote
Receive a tailored pricing based on your needs.
- Choose license type
- Multiple user options
- Custom scope & coverage
- Fast turnaround
"Designing Growth Strategies is in our DNA"
The global continuous glucose monitoring market size was valued at USD 13.86 billion in 2025 and is projected to grow from USD 15.52 billion in 2026 to USD 33.61 billion by 2034, exhibiting a CAGR of 10.1% during the forecast period. North America dominated the continuous glucose monitoring market with a market share of 44.6% in 2025. Rising diabetes burden, broader clinical adoption of CGM across type 2 diabetes and insulin-using patients, and improving reimbursement and product access are accelerating growth in the continuous glucose monitoring market.
The continuous glucose monitoring market is entering a broader phase of clinical and commercial development. Adoption is extending beyond intensive insulin management into selected Type 2 diabetes populations. Product innovation, reimbursement policies, and digital healthcare integration are reshaping competitive priorities. Market growth will depend on clinical utility, affordability, sensor performance, and sustained access to monitoring.
The continuous glucose monitoring market size is closely linked to recurring sensor demand. Sensors generate repeat purchases through prescribed replacement cycles. Transmitters, receivers, readers, applicators, and accessories contribute additional revenue. Integrated disposable designs are changing component architectures. These systems can simplify handling while shifting revenue toward sensor assemblies.
Continuous Glucose Monitoring (CGM) systems are wearable or implantable medical devices that track glucose levels continuously or at frequent intervals, mainly through interstitial-fluid sensing, and relay readings to a receiver, smartphone, smartwatch, or connected insulin-delivery platform. CGM provides trend information, alerts, and a more complete view of glycemic patterns throughout the day and night. The market includes sensors and sensor assemblies, transmitters, receivers and readers, and applicators and accessories sold through prescription, over-the-counter, pharmacy, DME, and manufacturer-direct channels.
Market growth is being supported by the expanding diabetes population, wider reimbursement, rising use among people with type 2 diabetes, and the shift toward connected and automated diabetes management. The International Diabetes Federation estimated that 589 million adults aged 20-79 were living with diabetes in 2024, creating a large and expanding pool of potential users. Product miniaturization, longer sensor wear, simpler insertion, and smartphone connectivity are further improving acceptance.
Enzymatic electrochemical sensing dominates established commercial systems. Fluorescence-based optical sensing provides an alternative technology pathway, particularly for implantable devices. Product differentiation increasingly centers on accuracy, wear duration, calibration requirements, connectivity, and insertion experience. Compatibility with insulin pumps and automated delivery platforms also influences purchasing decisions.
Abbott Laboratories, DexCom, Inc., and Medtronic held the largest market share, driven by increased investments and strategic initiatives, including new launches, collaborations, and partnerships.
North America
North America led the global market, valued at USD 6.18 billion in 2025, supported by high diabetes prevalence, established reimbursement pathways, and rapid adoption of newer CGM technologies.
Europe
Europe is projected to reach USD 3.69 billion in 2026 and grow at a CAGR of 8.4%, driven by a large diabetes population of around 66 million adults.
Asia-Pacific
Asia-Pacific is projected to be valued at USD 3.79 billion in 2026, supported by a very large diabetes population and comparatively low CGM penetration in several major countries.
U.S.
The U.S. market is projected to reach USD 6.29 billion in 2026, capturing 40.5% of global revenues, supported by established reimbursement and strong physician acceptance.
Japan
Japan is projected to generate approximately USD 0.72 billion in 2026, contributing nearly 4.6% of global revenues.
China
China is set to reach approximately USD 1.39 billion in 2026, contributing about 9.0% of global revenues and ranking as a key national market in Asia Pacific.
Read More
Longer-Wear Sensors, AI-Enabled Insights, and Connected Ecosystems to Transform CGM Use
The market is moving toward longer-wear, smaller, smarter, and more connected glucose-sensing platforms. Manufacturers are extending sensor life to reduce replacement burden while embedding greater intelligence into companion applications and connected care ecosystems. Senseonics’ Eversense 365, approved in the U.S. in 2024 and commercially launched in Europe in 2026, demonstrates the shift toward year-long implantable monitoring, while newer transcutaneous systems are also extending wear duration.
The continuous glucose monitoring market is shifting toward integrated, lower-profile sensor designs. Manufacturers are reducing device size and simplifying insertion. Disposable all-in-one systems remove separate transmitter handling, changing component-level revenue structures. Longer sensor wear is another defining trend. Extended wear can reduce replacement frequency and simplify management. Implantable systems offer an alternative by reducing routine sensor changes. Adoption depends on procedure access, clinical preference, and convenience.
At the same time, software is becoming a more important part of the user experience. Dexcom introduced a generative-AI platform for Stelo in 2024 to provide more personalized glucose-related insights, reflecting the broader movement toward predictive analytics and individualized guidance. Integration with smartphones, smartwatches, insulin pumps, automated insulin-delivery systems, and cloud-based clinician platforms is also increasing. Consequently, competition is increasingly being shaped by sensor accuracy, wear convenience, interoperability, personalized interpretation, connectivity, and the ability to integrate continuous monitoring naturally into daily diabetes management.
Connectivity is becoming a core product attribute. Smartphone applications, cloud platforms, and remote data sharing support engagement between clinical visits. Clinicians can review glucose patterns remotely and identify changes requiring intervention. Interoperability is an increasingly important competitive factor. The market is expanding beyond traditional prescription pathways. Over-the-counter products create access routes for selected non-insulin users. Their positioning requires clear distinctions between wellness insights and medical functions intended to guide treatment decisions.
Download Free sample to learn more about this report.
Increasing Diabetes Burden and Broader CGM Adoption to Propel Market Growth
The growing burden of diabetes, together with broader clinical use of CGM, is a central factor driving continuous glucose monitoring market growth. CGM adoption was initially concentrated among people with type 1 diabetes and those using intensive insulin therapy. Still, its role is widening across type 2 diabetes, basal-insulin users, and selected non-insulin populations. This expansion is being reinforced by easier product access, improving reimbursement, and a stronger focus on time-in-range and day-to-day glucose variability rather than isolated glucose measurements.
The continuous glucose monitoring industry benefits from a growing emphasis on glucose patterns rather than isolated measurements. Continuous data reveals overnight changes, post-meal excursions, and time outside target ranges. These insights support treatment adjustments that intermittent testing may not capture. They are particularly relevant for people using intensive insulin regimens. Automated insulin delivery is another important demand driver. These platforms rely on frequent sensor readings to inform insulin delivery. Their performance depends on dependable data transmission, sensor accuracy, and predictable operating characteristics. This relationship creates demand for compatible sensors and integrated monitoring ecosystems.
The commercial momentum of major manufacturers also reflects this wider adoption. Dexcom reported serving approximately 3.5 million customers globally at the end of 2025, while Abbott reported USD 6.8 billion in Diabetes Care revenue for 2024, with FreeStyle Libre serving as a major growth platform. As physicians increasingly use CGM data to personalize treatment and patients become more comfortable with wearable monitoring, the technology is moving from a specialized diabetes-management tool toward a broader standard of care, supporting sustained demand for sensors and related components.
The expanding focus on Type 2 diabetes management is widening the addressable patient population. Earlier monitoring can help clinicians assess treatment response and lifestyle-related glucose patterns. Adoption, however, depends on clinical suitability, affordability, and reimbursement. Broader access therefore requires differentiated products and care pathways.
Market Drivers - Impact & CAGR Contribution (2026–2034)
| Rank | Market Driver | Overall Impact Rank | CAGR Contribution (2026–2034) | Impact: 2026-2028 | Impact: 2029-2031 | Impact: 2032-2034 |
|---|---|---|---|---|---|---|
| 1 | Growth in clinical genomic testing and precision medicine | High | 3.10% | High | High | High |
| 2 | Expansion of hereditary cancer, reproductive, and rare-disease counseling demand | High | 2.35% | High | High | High |
| 3 | Expansion of genetic counselor capacity and hospital genetics programs | Medium-High | 1.95% | Medium-High | High | High |
| 4 | Tele-genetic and digital service delivery | Medium | 1.55% | Medium | High | High |
| 5 | Reimbursement expansion and national genomics initiatives | Medium-Low | 1.20% | Medium | Medium | High |
| 6 | Others (cascade testing, preventive genomics, employer programs, workflow integration and awareness) | Low | 0.70% | Low | Low | Medium |
| Total Positive Growth Contribution | 10.85% | |||||
Source: Fortune Business Insights
Download Free sample For In-Depth Market Restraints & Risk Analysis
High Recurring Costs and Uneven Reimbursement to Limit Wider Adoption
Despite strong clinical acceptance, the recurring cost of CGM remains a meaningful restraint, particularly in markets where reimbursement is limited, fragmented, or tied to narrow eligibility criteria. Continuous use requires repeated sensor purchases, while some systems also involve transmitters, receivers, insertion procedures, or subscription-related costs. For patients without adequate insurance coverage, these recurring expenses can make long-term adherence difficult, especially when lower-cost blood glucose meters remain available.
Affordability remains a restraint across the continuous glucose monitoring market. Sensors require recurring replacement, creating ongoing costs for patients and payers. Where reimbursement is limited, these expenses can restrict adoption. Even covered users may face eligibility rules, co-payments, or supply limits that interrupt use. Clinical performance also requires careful management. Sensors estimate glucose in interstitial fluid, which can lag behind blood glucose during rapid changes. Accuracy may vary with sensor age, placement, operating conditions, and individual physiology. These factors can reduce confidence and require clear guidance on interpreting readings and confirming unexpected results.
Reimbursement rules also vary considerably between countries and even across payers within the same country, creating uneven access. In the U.S., Medicare coverage of CGM supplies is linked to specific eligibility and durable medical equipment requirements. CMS states that the supply allowance is not covered when a beneficiary never uses a qualifying DME receiver or insulin infusion pump to display CGM data. These conditions can slow penetration among lower-income groups and users in less-developed reimbursement environments. Longer-wear sensors, pharmacy access, and direct-to-consumer models are helping, but affordability remains a barrier to population-level adoption.
Market Restraints - Impact & Negative CAGR Contribution (2026–2034)
| Rank | Market Restraints | Overall Impact Rank | Negative CAGR Contribution (2026–2034) | Impact: 2026-2028 | Impact: 2029-2031 | Impact: 2032-2034 |
|---|---|---|---|---|---|---|
| 1 | High recurring sensor costs and uneven reimbursement or affordability across countries and patient groups | High | -1.10% | High | High | Medium |
| 2 | Sensor accuracy, reliability, skin-tolerance, adherence, and product recall-related concerns | Medium-High | -0.80% | High | Medium | Medium |
| 3 | Complex regulatory, cybersecurity, interoperability, and clinical-validation requirements | Medium | -0.60% | Medium | Medium | High |
| 4 | Others (pricing pressure, supply-chain interruptions, data overload, limited awareness in underpenetrated markets, switching barriers) | Low | -0.40% | Low | Low | Low |
| Total Negative Growth Impact | -2.90% | |||||
Source: Fortune Business Insights
Download Free sample For In-Depth Market Restraints & Risk Analysis
Expansion into Non-Insulin Type 2 Diabetes and OTC Use to Create New Revenue Opportunities
A major growth opportunity lies in extending CGM beyond the traditional insulin-treated diabetes population. Large numbers of people with type 2 diabetes who do not use insulin, along with individuals with prediabetes or other forms of dysglycemia, remain underpenetrated by continuous monitoring. Regulatory changes are beginning to open this population to new products and commercial models. In August 2024, Dexcom launched Stelo in the U.S. as an over-the-counter glucose biosensor for adults not using insulin, removing the prescription requirement for its intended population.
Type 2 diabetes represents a substantial opportunity for market expansion. Many patients do not use intensive insulin therapy but still experience variable glucose patterns. Products designed around simpler workflows, lower costs, and appropriate clinical guidance could improve access. Reimbursement and clinical evidence will determine the pace of adoption.
Emerging economies offer another growth pathway. Diabetes prevalence is increasing while digital health infrastructure and specialist services continue to develop. Local manufacturing, regional distribution partnerships, and lower-cost product configurations may improve affordability. Companies must also address reimbursement gaps and uneven clinical training.
Abbott has similarly expanded into over-the-counter monitoring with Lingo and Libre Rio, broadening glucose sensing toward diabetes management and metabolic-health applications. This creates room for manufacturers to develop consumer-facing channels, subscription programs, digital coaching tools, and pharmacy-led access models. Over time, stronger evidence around behavioral modification, treatment optimization, and earlier glycemic intervention could support wider adoption in primary care and preventive health, substantially increasing the addressable population beyond intensive insulin management.
Sensor innovation offers further differentiation. Longer wear, improved accuracy, reduced calibration burden, and better adhesive performance can strengthen product value. Implantable sensing may suit users seeking fewer routine replacements. These approaches require evidence supporting their cost and clinical positioning.
Maintaining Accuracy, Reliability, and Digital Safety at Scale to Remain a Key Challenge for Manufacturers
As CGM becomes more deeply integrated into treatment decisions and automated insulin delivery, manufacturers face a growing challenge in maintaining sensor accuracy, software reliability, cybersecurity, and uninterrupted data delivery at scale. Small errors can carry greater clinical consequences when glucose readings are used to guide insulin dosing or trigger automated responses. The FDA’s 2025 correction involving certain Dexcom G7 and ONE+ applications highlighted how a software-design issue could result in missed sensor-failure alerts.
Abbott also initiated a 2025 correction for certain FreeStyle Libre 3 and Libre 3 Plus sensors after identifying the potential for incorrect low glucose readings related to a manufacturing issue. These developments underline the need for robust quality systems spanning sensor chemistry, manufacturing, firmware, mobile applications, and wireless connectivity. As portfolios expand across more countries and clinical populations, companies must also manage differing regulatory and post-market surveillance requirements. Sustaining user confidence will therefore depend on consistent real-world performance, rapid corrective action, secure connectivity, manufacturing control, and transparent communication with patients and healthcare professionals.
The continuous glucose monitoring market is segmented by product architecture, sensing technology, clinical indication, and distribution channel. Each dimension shapes purchasing behavior, recurring revenue, and competitive positioning. Product design determines replacement economics, while clinical indication influences monitoring intensity and reimbursement. Distribution structures affect affordability, supply continuity, and access to care.
Recurring Sensor Replacement and Expanding User Base to Keep Sensors and Sensor Assemblies Dominant
Based on product type, the market is segmented into sensors and sensor assemblies, transmitters, receivers and readers, and applicators and accessories.
Sensors and Sensor Assemblies
The sensors and sensor assemblies segment is expected to account for the largest continuous glucose monitoring market share in the coming years, as sensors are the recurring-use component of most CGM systems. Transcutaneous sensors generally require regular replacement, creating a steady replenishment cycle and high annual revenue per active user. The expanding installed CGM user base further magnifies sensor demand.
Sensors and sensor assemblies represent the principal recurring product category. Their replacement cycles create repeat demand, linking revenue to the installed user base, prescribed wear duration, and patient persistence. Sensor accuracy and reliability directly influence clinical confidence and continued use.
Manufacturers compete through wear time, insertion simplicity, adhesive performance, miniaturization, and signal stability. Smaller assemblies may improve comfort and reduce device visibility. Longer wear periods can lower replacement frequency, simplify fulfillment, and reduce the burden of routine device changes.
Integrated disposable designs combine sensing and transmission functions within a single assembly. This architecture simplifies handling and reduces dependence on separate reusable components. It also changes manufacturing economics, inventory management, and revenue allocation across product categories.
Transmitters
Transmitters convert sensor signals into data displayed through a receiver, reader, or smartphone. Their role depends on product architecture. Some systems use reusable transmitters, while integrated disposable designs incorporate transmission functions into the sensor assembly.
Reusable transmitters can generate replacement and upgrade demand. Their value depends on durability, battery performance, wireless reliability, and compatibility. Integrated systems reduce separate handling but increase the technical requirements placed on disposable units. These differences influence procurement and manufacturing decisions.
Connectivity is central to transmitter performance. Reliable communication supports alerts, remote monitoring, data sharing, and automated insulin delivery. Interruptions can weaken confidence and disrupt treatment workflows. Manufacturers must also address cybersecurity and compatibility across connected devices.
Standalone transmitter demand may decline in portfolios shifting toward all-in-one systems. However, transmitters remain relevant in architectures that separate sensing and communication. Backward compatibility can protect existing users while manufacturers introduce newer platforms.
Receivers and Readers
Receivers and readers provide dedicated interfaces for viewing glucose information. They remain relevant for users without compatible smartphones, those preferring separate medical devices, and settings requiring controlled workflows. Their importance varies with age, digital literacy, and local technology access.
Dedicated readers can simplify access for patients who do not use smartphones consistently. They may also support structured device initiation in hospitals and clinics. However, separate hardware creates procurement, inventory, and replacement requirements. Smartphone applications can reduce this burden when compatibility is reliable.
Manufacturers increasingly position readers alongside mobile applications and cloud-based reporting. Data sharing and remote review influence product design. The segment's competitiveness depends on accessibility, interface simplicity, and integration with clinical systems.
Healthcare providers may use readers during training and follow-up. A dedicated interface can support patients who need simpler workflows. However, data transfer and software updates must remain manageable. Poor integration can increase administrative workload and reduce the value of connected monitoring.
Applicators and Accessories
The applicators and accessories segment is projected to grow at a CAGR of 11.3% during the forecast period. Applicators and accessories support insertion, adhesion, protection, and routine sensor use. Their revenue contribution may be smaller than sensors, but they influence user satisfaction and persistence. Consistent insertion tools can reduce application errors and improve placement reliability.
Adhesive patches, skin barriers, overpatches, and protective accessories address practical wear challenges. Sweat, movement, bathing, and skin sensitivity can affect sensor retention. Accessories therefore support use across different activity levels and environmental conditions.
Demand generally follows sensor shipments and replacement frequency. Some accessories are bundled with devices, while others are purchased separately. Better adhesive design and simpler application can strengthen product value. Compatibility also matters when users change sensor platforms.
To know how our report can help streamline your business, Speak to Analyst
Proven Performance and Manufacturing Scale to Sustain Enzymatic Electrochemical Sensing Leadership
By technology, the market is classified into enzymatic electrochemical sensing, fluorescence-based optical sensing, and others.
Enzymatic Electrochemical Sensing
Enzymatic electrochemical sensing is expected to hold the largest market share over the forecast period, as it underpins the dominant transcutaneous CGM platforms and combines established sensor chemistry with scalable, miniaturized electronics. The technology supports frequent glucose measurements, factory calibration, wireless transmission, and compact disposable form factors. Moreover, the segment is projected to hold a 99.6% share in 2026.
Enzymatic electrochemical sensing is the dominant technology platform across commercial continuous glucose monitoring systems. These sensors use an enzyme-mediated reaction to generate an electrical signal associated with glucose concentration. Signal-processing systems convert this response into readings for users and connected applications.
Commercial maturity supports broad deployment. Manufacturers have established production methods, regulatory experience, and clinical validation pathways. Engineering priorities include signal stability, accuracy, miniaturization, and sensor longevity. Improvements in membranes and sensor chemistry can help manage interference and performance variation.
The technology is suitable for wearable systems and established automated insulin delivery ecosystems. Clinical familiarity supports adoption among endocrinologists and diabetes care teams. However, performance depends on sensing-interface stability and consistent manufacturing quality.
Fluorescence-based Optical Sensing
The fluorescence-based optical sensing segment is estimated to grow at a CAGR of 21.6% during the forecast period. Fluorescence-based optical sensing represents a differentiated technology pathway. It uses optical responses associated with glucose concentration rather than relying solely on electrochemical measurement. The approach has been commercialized in implantable monitoring platforms.
Optical sensing may support extended sensor duration. Implantable systems can reduce the frequency of external sensor replacement. However, placement and removal require a clinical procedure. This creates a different adoption profile from wearable sensors inserted by users.
Commercial development depends on optical stability, biocompatibility, signal consistency, and reliable calibration. Long-term performance requires clinical evidence. The approach may appeal to users who prioritize fewer routine sensor replacements.
Large Patient Pool to Drive Type 2 Diabetes Dominance
By clinical indication, the market is classified into type 1 diabetes, type 2 diabetes, gestational diabetes, and others.
Type 1 Diabetes
Type 1 diabetes is a foundational indication for continuous glucose monitoring. Patients generally require ongoing insulin therapy and frequent glucose assessment. Continuous data supports insulin adjustment, hypoglycemia detection, and evaluation of time spent within target ranges.
Demand is supported by clinical familiarity and integration with insulin pumps. Automated insulin delivery systems rely on continuous sensor inputs. This creates a strong relationship between sensor adoption and connected insulin technologies.
Pediatric use is also important. Caregivers may use remote monitoring features to review glucose patterns and respond to alerts. This increases the value of reliable connectivity and data sharing. Device comfort and adhesive performance remain important for long-term use.
The segment is relatively mature in several developed markets. Future growth will depend on improved access, product upgrades, and broader reimbursement. Accuracy and interoperability will remain key purchasing considerations.
Type 1 users often depend on continuous data throughout the day and night. Sensor interruptions can complicate insulin management. Reliability and alert performance therefore carry substantial clinical importance. Manufacturers must maintain dependable supply and technical support.
The indication also supports integrated technology ecosystems. Compatibility between sensors, pumps, and algorithms can reduce manual intervention. However, interoperability remains a competitive and regulatory consideration. Connected components must demonstrate reliable performance as a system.
Type 2 Diabetes
Type 2 diabetes is expected to hold the largest share over the forecast period, as it represents the largest diabetes population and CGM use is extending well beyond intensive insulin therapy. Moreover, the segment is projected to hold a 54.3% share in 2026.
Type 2 diabetes offers a broad opportunity because its patient population is substantially larger than the Type 1 population. Adoption behavior, however, is more varied. Monitoring needs differ according to disease duration, treatment intensity, hypoglycemia risk, and clinical objectives.
Patients using intensive insulin regimens are an established user group. Wider adoption among people using basal insulin or non-insulin therapies requires evidence of clinical and economic value. Simpler devices and lower recurring costs may improve uptake.
Continuous monitoring can help clinicians assess responses to medication, diet, and physical activity. It may also reveal glucose variability that periodic testing does not capture. Monitoring frequency should align with treatment goals and individual clinical needs.
Over-the-counter products may broaden access among selected non-insulin users. Their positioning must remain distinct from devices intended to guide insulin dosing. Expansion depends on reimbursement, clinical guidance, affordability, and responsible communication.
Gestational Diabetes
The gestational diabetes segment is estimated to grow at a CAGR of 12.2% during the forecast period. Gestational diabetes is a targeted clinical application with distinct monitoring requirements. Maternal glucose control is important during pregnancy. Continuous monitoring may provide additional information about daily glucose patterns and treatment response.
Adoption is influenced by obstetric practice, endocrinology support, and local clinical protocols. Some care pathways continue to rely primarily on capillary blood glucose testing. Wider use requires evidence that continuous data improves relevant maternal or neonatal outcomes.
Shorter treatment periods create a different demand pattern from lifelong diabetes management. Sensor supply must align with pregnancy duration and clinical need. Cost and reimbursement can determine whether monitoring is routine or selective.
The segment offers an opportunity for targeted clinical validation. Device comfort, accuracy, and ease of use are important during pregnancy. Clear guidance is necessary because treatment decisions may depend on specific clinical thresholds.
Convenient Access and Expanding Consumer Availability to Boost Retail and Specialty Pharmacies Segment Growth
On the distribution channel, the market is classified into retail and specialty pharmacies, DME and medical supply distributors, manufacturer-direct channels, and others.
Retail and Specialty Pharmacies
Retail and specialty pharmacies are expected to account for the largest share over the forecast period, as CGM shifts from a specialist-device model toward routine outpatient diabetes management. Pharmacy access reduces procurement friction, allows patients to obtain sensors alongside other diabetes therapies, and can simplify access compared with traditional equipment channels. Furthermore, the segment is set to hold a 48.9% share in 2026.
Retail and specialty pharmacies provide established routes for sensor dispensing and recurring refills. Specialty pharmacies can assist with prior authorization, benefits verification, and product education. Reliable inventory and refill coordination help prevent monitoring interruptions. Over-the-counter products may further expand retail participation, although consumer guidance and appropriate product positioning remain essential.
DME and Medical Supply Distributors
Durable medical equipment (DME) and medical supply distributors serve patients whose coverage routes devices through equipment benefits. They manage documentation, eligibility checks, fulfillment, and recurring shipments. Payer relationships and administrative expertise support their position. Delays in authorization or delivery can interrupt sensor use and weaken patient retention.
Manufacturer-direct Channels
The manufacturer-direct channels segment is projected to grow at a CAGR of 13.8% during the forecast period. Manufacturer-direct channels allow companies to manage sales, subscriptions, education, and customer relationships. Digital ordering can simplify repeat purchases, particularly for cash-pay and selected consumer products. Direct distribution requires investment in logistics, service, and compliance. Manufacturers must balance channel control with established pharmacy and distributor relationships.
Based on geography, the market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America Continuous Glucose Monitoring Market Size, 2025 (USD Billion)
To get more information on the regional analysis of this market, Download Free sample
North America held the largest revenue share in 2024, at USD 5.45 billion, and was valued at USD 6.18 billion in 2025. Market growth is supported by high diabetes prevalence, established reimbursement pathways, strong physician acceptance, and rapid adoption of newer CGM technologies in the U.S. and Canada. The International Diabetes Federation projects the number of people with diabetes in the North America & Caribbean region to increase by approximately 22% by 2050, sustaining the long-term addressable patient base.
North America benefits from established diabetes technology adoption, specialist care networks, and developed reimbursement systems. The United States drives regional demand, while Canada contributes through public and private coverage pathways. Competition centers on accuracy, integration, and recurring supply. Access remains uneven across payer groups. Future growth depends on broader Type 2 diabetes adoption, affordability, and sustained reimbursement support.
In 2026, the U.S. market is projected to represent USD 6.29 billion, capturing 40.5% of total global revenues. The United States is a leading commercial market, supported by clinical awareness and established device manufacturers. Medicare and private payer policies influence eligibility and channel selection. Over-the-counter clearances are expanding selected access pathways. Competition is intensifying around integrated systems, sensor duration, and consumer positioning. Coverage restrictions and out-of-pocket costs continue to shape adoption among non-intensive insulin users.
Europe is expected to achieve a CAGR of 8.4% in the coming years, the second-highest globally, reaching USD 3.69 billion in 2026. The IDF estimates that around 66 million adults in Europe are living with diabetes, with the number expected to increase by about 10% by 2050, providing a sustained clinical demand base.
Europe combines mature diabetes technology markets with varied national reimbursement systems. Adoption is supported by public healthcare infrastructure and specialist diabetes services. Procurement decisions differ across countries, affecting pricing and product access. Manufacturers must demonstrate clinical value and cost-effectiveness. Growth opportunities include wider Type 2 diabetes use, improved interoperability, and expanded access in markets with lower technology penetration.
Germany Continuous Glucose Monitoring Market
The market in Germany is projected to reach about USD 0.70 billion in 2026, representing roughly 4.5% of global revenues. Germany benefits from a developed medical technology sector and established diabetes care infrastructure. Reimbursement rules and statutory health insurance decisions influence access. Specialist practices and diabetes centers support device education and treatment integration. Competition focuses on product performance, service reliability, and compatibility with insulin delivery systems. Future adoption will depend on clinical evidence, coverage decisions, and patient affordability.
The U.K. market is projected to reach USD 0.55 billion in 2026, accounting for 3.5% of global revenues. The United Kingdom's market is shaped by National Health Service procurement, clinical guidance, and regional implementation. Access varies according to eligibility criteria and local service capacity. Established diabetes technology pathways support adoption among insulin-treated patients. Wider use requires budget justification and clinical workforce support. Product suppliers must address procurement value, interoperability, and equitable access across healthcare systems.
In 2026, the Asia Pacific market is predicted to be valued at USD 3.79 billion, ranking as the third-largest globally. The market offers substantial growth potential, as it combines an exceptionally large diabetes population with comparatively lower CGM penetration in several major countries.
Asia-Pacific offers substantial long-term potential due to diabetes prevalence, expanding healthcare capacity, and rising digital health adoption. Market maturity varies widely between countries. Japan, China, and Australia have distinct reimbursement and regulatory environments. Affordability remains a central constraint. Local manufacturing, clinician education, and partnerships may improve access and support regional market growth. The market in India is set to reach approximately USD 0.43 billion in 2026, corresponding to about 2.8% of global revenues.
The market in Japan is projected to generate approximately USD 0.72 billion in 2026, contributing nearly 4.6% of global revenues. Japan has advanced medical technology capabilities and an established diabetes care system. Clinical adoption is influenced by physician guidance, reimbursement, and product usability. Demand includes patients requiring intensive insulin management and those benefiting from closer glucose assessment. Manufacturers must meet stringent regulatory and quality expectations. Compact designs, reliable performance, and integration with digital care may support future expansion.
The market in China is set to reach approximately USD 1.39 billion in 2026, contributing about 9.0% of global revenues. China represents a significant opportunity because of its large diabetes population and expanding medical device sector. Adoption is influenced by affordability, hospital access, and regional reimbursement differences. Domestic manufacturers are increasing competition through local product development and distribution. Clinical education remains important. Market growth will depend on reliable sensor supply, regulatory compliance, and broader access beyond major urban centers.
Latin America and the Middle East & Africa are anticipated to witness moderate market growth, with Latin America expected to reach around USD 0.70 billion in 2026. The Latin America market is expected to grow from a comparatively smaller base as the diabetes burden rises and advanced glucose-monitoring technologies become more accessible in major markets such as Brazil and Mexico. The Middle East & Africa market is expected to expand as a high and rapidly increasing diabetes burden combines with relatively low current penetration of advanced glucose-monitoring technologies.
Latin America's market remains uneven due to differences in healthcare funding, insurance coverage, and specialist access. Private healthcare demand is more developed in selected urban markets. Public procurement and reimbursement can influence broader adoption. Price-sensitive purchasing favors affordable systems and dependable distribution. Local partnerships, clinician training, and improved coverage could strengthen access over the forecast period.
The Middle East and Africa show varied adoption, shaped by healthcare investment and purchasing power. Gulf markets benefit from advanced hospitals and private care capacity. Other countries face affordability and distribution constraints. Demand is supported by diabetes management needs. Wider access requires local partnerships, clinician education, reimbursement development, and reliable supply chains.
In 2026, the GCC market is expected to generate approximately USD 0.20 billion, accounting for nearly 1.3% of global revenues.
Strong Market Concentration and Continuous Product Innovation to Intensify Competition
The global continuous glucose monitoring market has a relatively concentrated competitive structure, led primarily by Abbott Laboratories, DexCom, Inc., and Medtronic, which benefit from large installed user bases, established reimbursement access, extensive distribution networks, and strong integration with digital diabetes-management ecosystems.
Competition is increasingly shifting beyond basic glucose-monitoring accuracy toward longer sensor wear, smaller form factors, lower cost, factory calibration, smartphone connectivity, OTC availability, predictive analytics, and interoperability with automated insulin-delivery systems. Roche is strengthening competition through its AI-enabled Accu-Chek SmartGuide, while Senseonics differentiates itself through the 365-day implantable Eversense system. Regional manufacturers, particularly from Asia, are also increasing pricing pressure and expanding CGM availability, making technological differentiation, reimbursement access, manufacturing scale, and geographic expansion increasingly important competitive factors.
The continuous glucose monitoring industry is led by companies with established sensor platforms, regulatory experience, clinical evidence, and global distribution. Abbott and Dexcom hold prominent positions in wearable sensor systems. Their strategies emphasize accuracy, ease of use, product breadth, and recurring sensor sales. Both companies are pursuing opportunities beyond traditional intensive insulin management.
Medtronic occupies an important position through its diabetes technology ecosystem. Its competitive proposition connects continuous monitoring with insulin pumps, smart pens, and automated insulin delivery. Partnerships can expand product choice while strengthening platform integration. Its collaboration with Abbott illustrates the strategic value of combining sensor technology with insulin delivery expertise.
Senseonics differentiates through implantable, long-duration sensing. Its Eversense platform targets users seeking fewer routine sensor replacements. The model depends on clinical procedures and trained providers. This creates a distinct commercial pathway from disposable wearable systems.
The report provides an in-depth analysis of all continuous glucose monitoring market segments, highlighting key drivers, trends, opportunities, restraints, and challenges. It also provides insights into technological advancements, key industry developments, company market share analysis, and profiles of leading companies. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth and advancement of the market over recent years.
Request for Customization to gain extensive market insights.
| ATTRIBUTE | DETAILS |
| Study Period | 2021-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2021-2024 |
| Growth Rate | CAGR of 10.1% from 2026 to 2034 |
| Unit | Value (USD Billion) |
| Segmentation | By Product Type, By Technology, By Clinical Indication, By Distribution Channel, and Region |
| By Product Type |
|
| By Technology |
|
| By Clinical Indication |
|
| By Distribution Channel |
|
| By Region |
|
Approach 1: Revenues and Market Share of Major CGM Players
Approach 2: Product Volume, Replacement Cycle, and Pricing Analysis
Approach 3: Patient Eligibility and CGM Adoption Model
Top-Down Approach
Approach 1: Country-Level Diabetes Burden and CGM Penetration Analysis
List of Key Sources
Primary Interviews
Supply-Side Interviews: 60%
Demand-Side Interviews: 40%
Final Market Triangulation
Fortune Business Insights says that the global market value stood at USD 13.86 billion in 2025 and is projected to reach USD 33.61 billion by 2034.
In 2025, the market value in North America stood at USD 6.18 billion.
The market is expected to exhibit a CAGR of 10.1% during the forecast period of 2026-2034.
By product type, the sensors and sensor assemblies segment is expected to lead the market over the forecast period.
The key factors driving the market are the rising diabetes burden and broader CGM adoption.
Abbott Laboratories, DexCom, Inc., and Medtronic are some of the major players in the market.
North America dominated the market in 2025.
Get 30-60 hrs Free Customization
Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.
Related Reports
Get In Touch With Us
US +1 833 909 2966 ( Toll Free )
Receive a tailored pricing based on your needs.
Discuss your questions with our industry experts.
Have questions? Get quick answers before you purchase.